In wealthier nations, over 80% of children diagnosed with cancer survive. Unfortunately, in some low- and middle-income countries, this survival rate drops significantly to just 20%.
During a UN General Assembly meeting in 2018, Dr. David G. Poplack, the founding director of Global HOPE (Hematology-Oncology Pediatric Excellence), learned that Teva supplies a substantial share of the medicines used to treat pediatric cancer—offering a chance to change this stark reality. This realization led to Teva’s partnership with Texas Children’s Hospital’s Global HOPE initiative.
Global HOPE follows a sustainable model to improve cancer and blood disorder treatment for children, working to reduce disparities in care by:
Training healthcare professionals, including doctors and nurses Expanding access to vital medications Strengthening pediatric healthcare infrastructure During a UN General Assembly meeting in 2018, Dr. David G. Poplack, the founding director of Global HOPE (Hematology-Oncology Pediatric Excellence), learned that Teva supplies a substantial share of the medicines used to treat pediatric cancer—offering a chance to change this stark reality. This realization led to Teva’s partnership with Texas Children’s Hospital’s Global HOPE initiative.
Global HOPE follows a sustainable model to improve cancer and blood disorder treatment for children, working to reduce disparities in care by:
Between 2021 and 2024, Teva, with support from Direct Relief, provided around 1.5 million doses of medication—valued at approximately $27 million—to patients in Malawi, Uganda, Tanzania, Botswana, and Rwanda. These donations included roughly 20 different types of medicines, such as chemotherapy drugs, antifungals, anti-infectives, and hormone therapies. Additionally, during the COVID-19 pandemic, swift action was taken to ensure the continuous supply of essential medicines and medical resources to the region.
Beyond supplying medications, Teva also supports healthcare training programs to help professionals manage these treatments and improve patient access. In 2024 alone, 234 healthcare workers were trained, enabling them to diagnose 1,731 patients. Scholarships were also awarded to 11 nurses and a medical officer, while three workshops focused on professional well-being were conducted for 141 healthcare providers.
For Teva, collaborating with Global HOPE aligns with its broader mission to expand medicine accessibility. This objective is woven into the company’s business strategy, with some goals even tied to executive compensation and a sustainability-linked bond. To date, Teva has launched nine access-to-medicine initiatives worldwide—surpassing its original target of eight by 2025—helping more people in underserved regions obtain critical treatments.
Reflecting on the partnership before his retirement in 2024, Dr. Poplack emphasized its profound impact: “Throughout my career in pediatric oncology, I have witnessed many developments, but the collaboration between Global HOPE and Teva holds the greatest potential for medical advancement. Together, we have the opportunity to save tens of thousands of lives. By improving survival rates by 40%, we could save 40,000 children annually—an incredible achievement.”
Learn More:
Discover how we address global challenges and support communities while driving business success. Explore career opportunities and contribute to life-changing work. Beyond supplying medications, Teva also supports healthcare training programs to help professionals manage these treatments and improve patient access. In 2024 alone, 234 healthcare workers were trained, enabling them to diagnose 1,731 patients. Scholarships were also awarded to 11 nurses and a medical officer, while three workshops focused on professional well-being were conducted for 141 healthcare providers.
For Teva, collaborating with Global HOPE aligns with its broader mission to expand medicine accessibility. This objective is woven into the company’s business strategy, with some goals even tied to executive compensation and a sustainability-linked bond. To date, Teva has launched nine access-to-medicine initiatives worldwide—surpassing its original target of eight by 2025—helping more people in underserved regions obtain critical treatments.
Reflecting on the partnership before his retirement in 2024, Dr. Poplack emphasized its profound impact: “Throughout my career in pediatric oncology, I have witnessed many developments, but the collaboration between Global HOPE and Teva holds the greatest potential for medical advancement. Together, we have the opportunity to save tens of thousands of lives. By improving survival rates by 40%, we could save 40,000 children annually—an incredible achievement.”
Learn More: